Sofia, Bulgaria, October 26, 2022 – According to the requirements of art. 100t of LPOS, “Sopharma” AD notifies that the Board of Directors of "Sopharma" AD adopted a decision to initiate a procedure for the merger of the subsidiary "Biopharm-Engineering" AD, UIC: 119055339 in "Sopharma" AD under the conditions and in accordance with Chapter XVI of the Commercial Law and Art. 122 of the Law on the Public Offering of Securities. At the start of the procedure Sopharma AD owns 97.15% in the capital of the company.

Sofia, Bulgaria, October 5, 2022 – According to the requirements of art. 100t of LPOS, “Sopharma” AD notifies that for September 2022 the Company recorded a decrease in sales of 36% compared to the same month of the previous year, incl. 54% decrease in domestic sales and 23% decrease in export sales.

For the nine months since the beginning of the year the revenues from sales of products increase by 20%, incl. 17% increase of sales for the domestic market and 23% increase in export sales.